Premier Alternatives

Artios

Drug Discovery · Cambridge, United Kingdom · Founded 2015 · Privately Held (backing)

Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response. Artios is based in Cambridge, United Kingdom and was founded in 2015. It was valued at $260 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $385 million across 1 recorded round; the latest was an $114 million Series D in Nov 2025.

PMV mark · valuation
$260.3M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$384.5M
Last round
Later Stage VC (Series D)
Nov 2025

Artios key facts

as of Oct 2026
  • Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response.
  • Artios is valued at approximately $260.3M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $384.5M across 1 recorded rounds; the latest was Later Stage VC (Series D) ($114.4M) in Nov 2025.
  • Notable investors include RA Capital Management, Sofinnova Partners, M Ventures, The Invus Group, SV Health Investors — 27 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$260.3M

Valued at $260.3M at its later-stage round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Artios with a free account
  • ·The complete investor list: 27 names
  • ·Watch Artios: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Artios funding rounds

1 rounds
Nov 2025Later Stage VC (Series D)$114.4M▮
Full funding history →

Artios valuation

Artios was valued at $260 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Artios raised?

Artios has raised $385 million in total; 1 of its rounds is on record. The largest on record was an $114 million Series D in Nov 2025.

Artios investors

27 investors are on record for Artios, including RA Capital Management, Sofinnova Partners, M Ventures and The Invus Group. By type, the record holds 5 venture capital firms and 4 private equity firms. The Series D in Nov 2025 drew 15 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Convergent Therapeutics ($280 million), Edison Scientific ($255 million) and Wugen ($245 million).

About Artios

Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response. The company's treatments focus on developing therapies through deoxyribonucleic acid damage response pathways to help mutations in their DNA so that they can evolve, enabling physicians to selectively kill cancer cells through a concept known as synthetic lethality.

Industry
Drug Discovery
Sector
Healthcare
HQ
Cambridge, United Kingdom
Founded
2015
Employees
121
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.